

DAFTAR PUSTAKA

1. Johan K. Leukemia Mieloblastik Akut. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: Interna Publishing; 2014. p. 2671–5.
 2. Blum W, Bloomfield CD. Acute Myeloid Leukemia. 20th ed. New York: McGraw-Hill Education; 2018. 739–748 p.
 3. Iglesia Inigo S de la, Gomez Casares MT, Lopez Jorge CE, Lopez J, Martin P. New Molecular Markers in Acute Myeloid Leukemia. In: Myeloid Leukemia - Basic Mechanisms of Leukemogenesis. InTech; 2011.
 4. McKenna R, Kyle R, Kuehl W, Harris N, Coupland RF. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Swerdlow SH, editor. International Agency for Research on Cancer; 2008. 201 p.
 5. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2019 Jun;17(6):721–49.
 6. Magina KN, Pregartner G, Zebisch A, Wölfler A, Neumeister P, Greinix HT, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017 Aug 17;130(7):946–8.
 7. Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, et al. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol. 2023 Apr 1;149(4):1569–83.
 8. Jalbut MM, Brunner AM, Amrein PC, Ballen KK, Hobbs GS, Perry AM, et al. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Vol. 59, Leukemia and Lymphoma. Taylor and Francis Ltd; 2018. p. 988–91.
 9. Jimbu L, Valeanu M, Adrian T, Mesaros O, Bojan A, Dima D, et al. A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience. Cureus. 2023 Aug 20;
 10. Irawan C, Steven R, Gunarsa RG, Tenggara JB. Luaran Hasil Leukemia Mieloid Akut yang Menjalani Terapi pada Ruang Kemoterapi Semi-Isolasi. Jurnal Penyakit Dalam Indonesia. 2022 Oct 1;9(3):155.
 11. Kaushansky K, Lichtman MA, Prchal JT, Burns LJ, Press OW. William hematology. 9th ed. Philadelphia: McGraw-Hill Education; 2016. 1373–1436 p.
 12. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine. 19th ed. Philadelphia: McGraw-Hill Education; 2015. 678–687 p.
 13. Vakiti A, Reynolds SB, Mewawalla P. Acute Myeloid Leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK507875/>
- tiva SO. PENGARUH GENETIK, GAYA HIDUP DAN LINGKUNGAN
 DA KEJADIAN LEUKEMIA MIELOBLASTIK AKUT. JIMKI: Jurnal
 iah Mahasiswa Kedokteran Indonesia [Internet]. 2020;8(1):83–8.
 Available from: <https://bapin-ismki.e-journal.id/jimki/article/view/42>



15. Wachter F, Pikman Y. Pathophysiology of Acute Myeloid Leukemia. *Acta Haematol* [Internet]. 2024;147(2):229–46. Available from: <https://doi.org/10.1159/000536152>
16. Stubbins RJ, Francis A, Kuchenbauer F, Sanford D. Management of Acute Myeloid Leukemia: A Review for General Practitioners in Oncology. *Current Oncology*. 2022 Aug 30;29(9):6245–59.
17. Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dore GM. Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001–2019. *EClinicalMedicine* [Internet]. 2024;71. Available from: [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(24\)00128-7/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00128-7/fulltext)
18. Récher C, Röhlig C, Bérard E, Bertoli S, Dumas PY, Tavittian S, et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. *Leukemia*. 2022;36(4):913–22.
19. Master S, Mansour R, Devarakonda SS, Shi Z, Mills G, Shi R. Predictors of Survival in Acute Myeloid Leukemia by Treatment Modality. *Anticancer Res* [Internet]. 2016;36(4):1719–27. Available from: <https://ar.iiarjournals.org/content/36/4/1719>
20. Sultan S, Zaheer HA, Irfan SM, Ashar S. Demographic and Clinical Characteristics of Adult Acute Myeloid Leukemia - Tertiary Care Experience. 2016;(February).
21. Harani MS, Adil SN, Shaikh MU, Kakepoto GN, Khurshid M. Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. *J Ayub Med Coll Abbottabad*. 2005;17(1):26–9.
22. Albuquerque KMC de, Joventino CB, Moreira LC, Rocha HAL, Gurgel LA, Oliveira D de S, et al. Clinical outcome and prognosis of patients with acute myeloid leukemia submitted to chemotherapy with 5 years of follow-up. *Hematol Transfus Cell Ther*. 2024;46(1):8–13.
23. Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: A population-based study. *Haematologica*. 2012;97(12):1916–24.
24. Alsulami HA, Alnashri MM, Bawazir AF, Alrashid LT, Dly RA, Alharbi YA, et al. Prognostics and Clinical Outcomes in Patients Diagnosed With Acute Myeloid Leukemia (AML) in a Teaching Hospital. *Cureus*. 2021;13(10).
25. Dolatkhan R, Jam EI, Nikanfar A, Esfahani A, Chavooshi SH, Nejati B, et al. Outcome analysis of acute myeloid leukemia patients treated with high dose daunorubicin. *Biomedical Research and Therapy*. 2019;6(9):3347–51.
26. Mendoza-Urbano DM, Tello-Cajiao ME, Rosales J, Ahumada FE, Parra-Lara LG, Arrieta E. Survival in Elderly Patients Diagnosed With Acute Myeloid Leukemia: A Hospital-Based Study. *J Hematol*. 2023 Feb;12(1):7–15.
27. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. *Blood*. 2011;118(14):3832–41.



28. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. *Blood*. 2011;118(14):3832–41.
29. Löwenberg B, Pabst T, Vellenga E, Van Putten W, Schouten HC, Graux C, et al. Cytarabine Dose for Acute Myeloid Leukemia A b s t r a c t. Vol. 364, *N Engl J Med*. 2011.

